Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib Treatment
PHASE2Not yet recruitingINTERVENTIONAL
Enrollment
47
Participants
Timeline
Start Date
February 2, 2024
Primary Completion Date
September 30, 2029
Study Completion Date
September 30, 2029
Conditions
Non-Small Cell Lung Cancer Metastatic
Interventions
DRUG
Lazertinib
Lazertinib 240mg/day
DRUG
Tepotinib
Tepotinib 500mg/day
Trial Locations (1)
06351
Samsung Medical Center, Seoul
All Listed Sponsors
lead
Samsung Medical Center
OTHER
NCT06106802 - Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib Treatment | Biotech Hunter | Biotech Hunter